Story perspectives

FDA Panel to Vote on Peptide Compounding Amid Kennedy Push

7/22/2026

Summary

Story summary

The FDA advisory panel will vote on July 23–24 whether to permit compounding of seven peptides—TB-500, BPC-157, Semax, Epitalon, Emideltide, KPV and MOTs-C.
Health Secretary Robert F. Kennedy Jr. has urged loosening restrictions and says he has used the peptides.
FDA career scientists recommended against reclassifying any peptide because human safety and efficacy data are sparse.
Online wellness communities and influencers continue to promote the peptides, keeping consumer demand high despite limited clinical evidence.

1 of 1

Story summary

The FDA advisory panel will vote on July 23–24 whether to permit compounding of seven peptides—TB-500, BPC-157, Semax, Epitalon, Emideltide, KPV and MOTs-C.
Health Secretary Robert F. Kennedy Jr. has urged loosening restrictions and says he has used the peptides.
FDA career scientists recommended against reclassifying any peptide because human safety and efficacy data are sparse.
Online wellness communities and influencers continue to promote the peptides, keeping consumer demand high despite limited clinical evidence.